Guide · Updated November 2026

Compounded GLP-1 Quality: How to Verify Your Pharmacy

Compounded semaglutide and tirzepatide (GLP-1 receptor agonists sold as brand-name Wegovy, Ozempic, Mounjaro, and Zepbound) are still sold by some compounding pharmacies through telehealth providers. Quality varies widely. FDA-registered 503B outsourcing facilities are subject to federal CGMP requirements and FDA inspection, while 503A pharmacies are exempt from CGMP. Since both shortages ended, the FDA says neither drug is on its shortage list or the 503B bulks list, which sharply limits legal compounding. Patients should verify pharmacy type, accreditation, and batch testing before starting treatment.

I switched from brand-name Mounjaro to a compounded tirzepatide product for two months in late 2025 to test the experience firsthand. The medication worked. My DEXA results stayed consistent. But the process of figuring out whether the pharmacy behind my prescription was legitimate took more research than I expected. Most patients never do that research. This guide walks through exactly what to look for and what to avoid.

The compounded GLP-1 pharmacy quality question matters because not every pharmacy producing these medications operates at the same standard. Some run batch-level potency testing on every production run. Others do not. Novo Nordisk said in February 2026 that compounded injectable semaglutide it tested contained impurities of up to 86%. That figure comes from a company with a financial interest in discrediting compounders, so read it with care. Either way, patients need a way to evaluate quality for themselves.

Two Types of Compounding Pharmacies (and Why It Matters)

The single most important thing you can verify about your compounded GLP-1 is what type of pharmacy produces it. Under the Federal Food, Drug, and Cosmetic Act, there are two categories of compounding pharmacies, and the difference in oversight is significant.

503A pharmacies are traditional compounding pharmacies. They fill individual prescriptions for specific patients and, under section 503A, are exempt from federal CGMP requirements. They are licensed and inspected mainly by state boards of pharmacy, so oversight varies from state to state.

503B outsourcing facilities operate at a larger scale and are registered with the FDA. They are subject to Current Good Manufacturing Practice (CGMP) requirements, the framework that governs drug manufacturing, and the FDA inspects them on a risk-based schedule. They can produce medications in bulk and distribute to healthcare providers and facilities. The FDA’s leniency for 503B facilities making tirzepatide ended March 19, 2025, and for semaglutide on May 22, 2025, so a 503B facility should not be mass-producing copies of either drug now.

On paper, a 503B facility works under stricter federal quality rules than a 503A pharmacy. In practice, most compounded GLP-1 prescriptions today come from 503A pharmacies, which makes the checks below more important.

For context on the legal picture for compounded GLP-1s in 2026, that guide covers the shortage list timeline and enforcement actions.

The Quality Gap: What Testing Actually Looks Like

Here is what separates a high-quality compounding operation from a low-quality one.

High-Performance Liquid Chromatography (HPLC)

HPLC is the gold standard for verifying that a compounded medication contains the correct amount of active ingredient. The test measures potency (how much semaglutide or tirzepatide is actually in the vial) and identifies impurities or degradation products.

A well-run facility tests finished batches and can show you the result as a certificate of analysis. Ask what potency range the pharmacy accepts for a batch to pass, and whether your batch fell inside it.

A 503A pharmacy may or may not perform HPLC testing. Many rely on certificates of analysis from their raw ingredient suppliers, which verify the quality of the input material but not the finished product. This is a meaningful gap. A raw ingredient can be 99% pure and still end up in an improperly formulated final product if the pharmacy’s compounding process introduces errors.

Sterility Testing

Injectable medications need to be sterile. Contaminated injectables can cause infections, abscesses, and in rare cases, life-threatening sepsis. The 2012 New England Compounding Center outbreak, where contaminated steroid injections caused fungal meningitis and other infections, killed 64 people according to the CDC. It is the extreme example of what happens when compounding sterility fails.

503B facilities must meet CGMP requirements, which cover sterile production. 503A pharmacies are exempt from CGMP and follow state sterile compounding rules, so ask how they test each batch for sterility and endotoxins.

Beyond-Use Dating

Beyond-use dates (BUDs) tell you how long a compounded medication remains stable and potent after preparation. A pharmacy that has conducted stability studies on its formulations can assign longer, evidence-based BUDs. A pharmacy without stability data typically defaults to conservative USP guidelines.

This matters practically because a compounded GLP-1 vial that degrades faster than expected means you are injecting less active medication than you think. If your weight loss stalls unexpectedly on a compounded product, potency degradation is one possible explanation.

Red Flags: When to Walk Away

Not every compounded GLP-1 provider is equal. Reviewing telehealth providers for ClearMetabolic, I have seen patterns that separate trustworthy operations from questionable ones.

Prices Far Below Everyone Else

If one provider is far cheaper than the rest, ask where the savings come from. Sometimes it is a legitimate introductory offer. Sometimes it reflects cut corners on testing, ingredient sourcing, or pharmacy standards. See our compounded semaglutide page for typical pricing.

No Pharmacy Name Disclosed

A legitimate telehealth provider should tell you which compounding pharmacy fills your prescription. If a provider refuses to name the pharmacy or gives vague answers (“we work with multiple FDA-registered pharmacies”), that is a problem. You have a right to know who makes your medication.

Claims of “FDA-Approved” Compounded Medication

No compounded medication is FDA-approved as a finished product. The active ingredient (semaglutide or tirzepatide) is FDA-approved. The specific compounded formulation is not. Any provider claiming their compounded product is “FDA-approved” is either confused or deliberately misleading you. For a deeper look at the differences between compounded and brand-name GLP-1s, that guide breaks it down.

No Doctor Consultation

Compounded GLP-1s are prescription medications. A provider that ships them without a physician or nurse practitioner evaluation is operating outside legal boundaries. The consultation does not need to be in-person (telehealth is fine), but it needs to happen.

Extremely Long Supply Shipments

Getting a 90-day supply of a compounded injectable at once raises storage and stability questions. Check the beyond-use date on each vial. If the supply outlasts that date, the provider is shipping more than the pharmacy’s own stability data supports.

Your Verification Checklist

Before filling a compounded GLP-1 prescription, run through these steps. This takes about 15 minutes and can save you from wasting money on a substandard product.

Step 1: Identify the Pharmacy

Ask your telehealth provider: “Which compounding pharmacy fills my prescription?” Get the full name and location.

Step 2: Check Pharmacy Type and Registration

• For 503B facilities: Search the FDA’s Registered Outsourcing Facilities list to confirm registration. Check for any recent FDA warning letters or inspection findings.
• For 503A pharmacies: Verify the pharmacy holds an active license with its state board of pharmacy, and a license in your state if it ships to you. Ask whether it holds PCAB accreditation, a voluntary compounding accreditation.

Step 3: Ask About Testing

Request answers to these specific questions:

1. Do you perform HPLC potency testing on finished products (not just raw ingredients)?
2. How often? Every batch, or periodic sampling?
3. Can you provide a certificate of analysis for the batch my medication comes from?
4. What sterility testing protocol do you follow?
5. What are the beyond-use dates for your GLP-1 formulations, and are they based on stability studies?

A quality pharmacy will answer these questions directly. A pharmacy that dodges them or does not understand the questions is not where you want your injectable medication coming from.

Step 4: Verify the Provider’s Medical Process

Confirm that:

• A licensed physician, NP, or PA reviews your medical history before prescribing
• The clinician asks about your history and decides whether baseline lab work is needed
• Follow-up appointments are scheduled (not just a one-time prescription)
• The provider has a process for reporting adverse events

Compounded GLP-1 Pharmacy Quality Comparison

Here is how different pharmacy types and standards stack up:

Higher standards on paper do not guarantee a given vial. Ask for the batch result either way. For pricing across providers, see our cheapest GLP-1 guide.

What the Clinical Data Tells Us About Compounded Quality

No large-scale clinical trials have been conducted specifically on compounded semaglutide or tirzepatide. All the major efficacy and safety data comes from brand-name products.

The SURMOUNT-1 trial (NEJM, July 2022) studied brand-name tirzepatide in 2,539 adults with obesity and found 20.9% mean weight loss at the 15mg dose over 72 weeks. The STEP 1 trial (NEJM, February 2021) found 14.9% weight loss with brand-name semaglutide 2.4mg over 68 weeks. These results were achieved with pharmaceutical-grade medications produced under the strictest manufacturing conditions.

When you use a compounded version, you are making the pharmacological assumption that the same active ingredient at the same dose produces the same effect. This is generally valid. But “generally valid” depends on the compounded product actually containing the correct dose at the correct potency. That is exactly why HPLC batch testing matters.

I tracked my own results on compounded tirzepatide against my prior brand-name Mounjaro data. Over the two months I used the compounded product, my weight trajectory and DEXA scan results were consistent with what I had seen on brand-name. But I specifically chose a provider that uses a 503B pharmacy with published batch testing. I would not have been as confident with an untested 503A product.

What Novo Nordisk and Eli Lilly Say (and What to Make of It)

Both manufacturers have been vocal opponents of compounded GLP-1 medications. Novo Nordisk has published testing data claiming to find high impurity rates in compounded semaglutide samples. Eli Lilly sued compounders Strive and Empower and several telehealth companies in 2025 over tirzepatide copies.

These companies have legitimate points about quality control. They also have billions of dollars in revenue at stake, and every patient using a compounded alternative is a lost sale.

The truth sits in the middle. Some compounded products are genuinely substandard. Others may be well made, but no compounded product goes through FDA review, so you cannot assume either way without batch testing.

If you want to eliminate the quality question entirely, brand-name options have become more affordable. Zepbound vials and KwikPen from LillyDirect start at $299 a month for the 2.5mg dose, rising to $449 at higher doses with on-time refills (as of Nov 4, 2026). The Wegovy pill costs $149 a month at 1.5mg, $199 at 4mg and $299 at 9mg and 25mg through NovoCare (as of Nov 4, 2026). These narrow the price gap with compounded versions while offering full FDA oversight.

What to Do If Your Compounding Pharmacy Shuts Down

The compounded GLP-1 market has already seen pharmacy closures and FDA enforcement actions. If your pharmacy closes or your provider loses access to their compounding partner, you have options. Our guide on what to do when your compounding pharmacy shuts down covers the transition process in detail.

The short version: talk to your prescriber before any gap in treatment. In the STEP 1 extension, people who stopped semaglutide regained about two thirds of the weight they had lost within a year. Do not assume a compounded dose converts directly to a brand dose. Your prescriber decides the starting dose on a brand product, and it may be lower than what you were taking.

Bottom Line

Compounded GLP-1 quality ranges from excellent to questionable, and the difference comes down to the pharmacy behind your prescription. A 503B outsourcing facility works under federal CGMP rules and FDA inspection. A 503A pharmacy without accreditation or finished-product testing is a bigger gamble. Neither produces an FDA-approved product.

Before you fill a compounded semaglutide or tirzepatide prescription, spend 15 minutes running through the verification checklist above. Know your pharmacy’s name, type, and testing practices. If a provider will not tell you which pharmacy makes your medication, find a different provider.

For patients who want to compare providers that use verified compounding pharmacies, our provider directory includes pharmacy sourcing details where available.

FAQ

How do I know if my compounded GLP-1 is safe?

Ask your provider which pharmacy compounds the medication. Check whether the pharmacy is an FDA-registered 503B outsourcing facility or a state-licensed 503A pharmacy, and whether it holds PCAB accreditation. Request a certificate of analysis showing HPLC potency testing results for your medication batch. A legitimate pharmacy will provide this information.

What is the difference between a 503A and 503B compounding pharmacy?

503B outsourcing facilities are FDA-registered, are subject to CGMP requirements, and are inspected by the FDA. They can produce medications in bulk. 503A pharmacies are traditional compounding pharmacies, exempt from CGMP and overseen mainly by state boards, filling individual prescriptions.

Can I get batch testing results for my compounded semaglutide?

Yes. Ask your provider or the compounding pharmacy directly for a certificate of analysis (COA) for the batch your medication was produced in. A quality pharmacy will have HPLC potency testing, sterility testing, and endotoxin testing results available. If the pharmacy cannot or will not provide these, consider switching to a provider that uses a more transparent pharmacy.

Are compounded GLP-1 medications as effective as brand-name?

If the compounded medication contains the correct dose of the active ingredient at the labeled potency, it should produce comparable effects. All major clinical trial data (SURMOUNT-1 for tirzepatide, STEP 1 for semaglutide) used brand-name products. No large trials have tested compounded versions, so batch potency testing is the main way to check a compounded product.

What should I do if my compounded GLP-1 seems less effective than expected?

First, verify the dose and confirm proper storage (most compounded GLP-1s require refrigeration). If storage and dosing are correct, ask your pharmacy for batch testing results to check potency. If issues persist, talk to your prescriber about transitioning to a brand-name product. Do not raise your dose on your own.

Related

Guides:

• Compounded vs Brand-Name GLP-1 · Is Compounded Semaglutide Legal in 2026? · Compounding Pharmacy Closed?

Provider Reviews: MEDVi · Henry Meds · Hims

Compare: All Providers · Best GLP-1 Programs · Cheapest GLP-1 Online

What we checked

This AI-assisted public-source desk check reviewed FDA compounding law and GLP-1 policy pages, the FDA outsourcing facility registry, the SURMOUNT-1, STEP 1 and STEP 1 extension papers, a CDC outbreak release, Novo Nordisk’s February 2026 statement, Lilly and NovoCare self-pay price pages, and a public radio report on Lilly’s lawsuits on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.